TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37932258
Drug: BI 1467335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1467335 (≥3 mg)
Study: 37932443
Drug: Irinotecan dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan dosage adjusted based on UGT1A1 polymorphisms, specifically 370 mg/m² for *1/*1 genotype.
Study: 37932443
Drug: Irinotecan dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan dosage adjusted based on UGT1A1 polymorphisms.
Study: 37932443
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of irinotecan (180 mg/m²).
Study: 37932589
Drug: mesoglycan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesoglycan 50 mg bid
Study: 37932739
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg suramin
Study: 37932739
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg suramin
Study: 37932787
Drug: POINCARE-2 strategy
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POINCARE-2 strategy (daily weighing over 14 days, restriction of fluid intake, administration of diuretics, and/or ultrafiltration)
Study: 37932812
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion (500-mL saline infusion)
Study: 37932812
Drug: Norepinephrine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine dose increase
Study: 37933546
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (survey administered)
Study: 37933546
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no survey administered)
Study: 37934301
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) (3 sessions for 3 weeks, once a week, 1.8 bar, 10.0 Hz, 2000 impulses)
Study: 37934400
Drug: Individualized mat-Pilates
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized mat-Pilates sessions (45 min, twice weekly)
Study: 37934530
Drug: Specialty TUD
Normalized name: Tudorza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialty TUD services (including behavioral counseling and medications for tobacco treatment)
Study: 37934566
Drug: DWELL intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DWELL intervention (Facebook group providing practical solutions for home design for wellness)
Study: 37934611
Drug: Ceralasertib (AZD6738)
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib (AZD6738) 160 mg twice daily for 2 weeks in a 4-weekly cycle
Study: 37934611
Drug: Ceralasertib (AZD6738)
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib (AZD6738) at doses of 20-240 mg BD continuously or intermittently
Study: 37935109
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (≤20 ng/mL)
Study: 37935416
Drug: Cognitively stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitively stimulating semistructured conversations via internet/webcam 4 times per week for 6 months, then twice per week for an additional 6 months; plus weekly 10 minutes telephone check-ins
Study: 37935416
Drug: Weekly 10
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 10 minutes telephone check-ins
Study: 37935524
Drug: Niraparib in
Normalized name: Product containing niraparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib in combination with bevacizumab after carboplatin/paclitaxel
Study: 37935531
Drug: G-CBT (group-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CBT (group-cognitive behavioral therapy)
Study: 37935631
Drug: Abemaciclib in
Normalized name: Product containing abemaciclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib in combination with fulvestrant
Study: 37935977
Drug: Idarubicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin with higher dose cytarabine (IA)
Study: 37935977
Drug: Idarubicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin with higher dose cytarabine and vorinostat (IA+V)
Study: 37935977
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose cytarabine (with or without vorinostat)
Study: 37936126
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment (palliative intent)
Study: 37936126
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment (curative intent)
Study: 37936136
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects of drugs and duration of illness
Study: 37936166
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities
Study: 37936331
Drug: Antibacterial therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapeutic clothing (chitosan) + standard topical treatment
Study: 37936331
Drug: Antibacterial therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapeutic clothing (silver) + standard topical treatment
Study: 37936331
Drug: Standard therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapeutic clothing + standard topical treatment
Study: 37936408
Drug: Long-acting muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonist therapy
Study: 37936551
Drug: Adherence support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence support strategies including monthly counselling sessions with drug-level feedback (DLF), optional daily SMS reminders, weekly phone or SMS check-ins, peer support clubs, and additional counselling.
Study: 37936551
Drug: In-person clubs
Normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person clubs and weekly calls as support strategies.
Study: 37936652
Drug: Monovalent SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (10 μg of the spike protein from the ancestral D614 strain)
Study: 37936652
Drug: Monovalent SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant
Study: 37936687
Drug: QL1604 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1604 at 3 mg/kg Q2W
Study: 37936687
Drug: QL1604 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1604 at 3 mg/kg (Q2W and Q3W) and 200 mg (Q3W)
Study: 37936786
Drug: Anplag® 90mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anplag® 90mg (Ticagrelor) tablet
Study: 37936786
Drug: Brilinta® 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brilinta® 90 mg (Ticagrelor) tablet
Study: 37937444
Drug: Immunochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy with low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT)
Study: 37937763
Drug: Osimertinib-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib-chemotherapy
Study: 37938055
Drug: Blood lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood lead (BL) concentration measured by inductively coupled plasma mass spectrometry, baseline concentration 4.35 μg/dL, increased 3.17-fold over follow-up (median: 2.03 years; range: 0.92-6.45 years).
Study: 37938560
Drug: Intravenous methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylphenidate (fast delivery)
Study: 37938560
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (slow delivery)
Study: 37938561
Drug: Dendritic Cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic Cell (DC) vaccines
Study: 37938871
Drug: Group-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based acceptance and commitment therapy (ACT), 7 sessions of 45-60 min over 4 weeks
Study: 37939111
Drug: Inoserp PAN-AFRICA
Normalized name: African Pygeum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoserp PAN-AFRICA antivenom (IPA), administered 2 to 4 vials based on symptoms, renewed every 2 hours if needed.
Study: 37939133
Drug: Intravenous nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nivolumab followed by maximal safe resection and an intracerebral injection of ipilimumab alone or combined with nivolumab, biweekly adjuvant nivolumab up to five times.
Study: 37939141
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; 50/200/25 mg)
Study: 37939259
Drug: Intratumoral toll-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib
Study: 37940323
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of iodine-124 labeled amyloid-reactive peptide p5+14
Study: 37940357
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (7-day course)
Study: 37940387
Drug: Neuroform Atlas
Normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroform Atlas Stent System (used for treatment of proximal ICA aneurysms)
Study: 37940387
Drug: Neuroform Atlas
Normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroform Atlas Stent System (used for treatment of distal anterior circulation aneurysms)
Study: 37940433
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic therapy (10 days of broad-spectrum antibiotics: piperacillin/tazobactam converted to amoxicillin/clavulanic acid at discharge)
Study: 37940433
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic therapy
Study: 37940433
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative antibiotics (single dose before incision)
Study: 37940433
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative antibiotics
Study: 37940446
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks plus enzalutamide 160 mg orally once daily
Study: 37940936
Drug: Treviamet® &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treviamet® & Treviamet XR® (Sitagliptin with Metformin)
Study: 37941012
Drug: Stereotactic arrhythmia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic arrhythmia radioablation (STAR) with dose escalation from 27.0 Gy to a maximum of 35.1 Gy while keeping the planning target volume (PTV) dose constant at 25 Gy.
Study: 37941012
Drug: Stereotactic arrhythmia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic arrhythmia radioablation (STAR) with dose escalation.
Study: 37941087
Drug: Monthly social
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly social telephone call from a trained research assistant
Study: 37941113
Drug: Clazakizumab (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (humanized monoclonal antibody that neutralizes interleukin-6)
Study: 37941470
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI) 80 u twice weekly for 6 months
Study: 37941561
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy (NAST)
Study: 37941759
Drug: Hula intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hula intervention, 6 months, twice per week, 60 minutes each session, plus 60 minutes of home practice per week.
Study: 37941845
Drug: Paclitaxel-drug-coated balloon
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-drug-coated balloon (DCB) after bare-metal stent (BMS) implantation
Study: 37941979
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and nivolumab combination (10% after 2018)
Study: 37941979
Drug: Second-line medical
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line medical treatment
Study: 37942277
Drug: TNFi (tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi (tumor necrosis factor inhibitors)
Study: 37942314
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of AMG 212
Study: 37942314
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (CIV) administration of AMG 212
Study: 37942328
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg cadonilimab every 2 weeks plus lenvatinib (cohort A)
Study: 37942328
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg cadonilimab every 3 weeks plus lenvatinib (cohort B)
Study: 37942487
Drug: Dual intracerebroventricular
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual intracerebroventricular and intravitreal administration (specific dosage and duration not provided)
Study: 37942666
Drug: Grade IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade IV titanium (Ti) implants
Study: 37942793
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control for anticoagulation hypothesis)
Study: 37942793
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control for anti-inflammatory hypothesis)
Study: 37943221
Drug: Best practice
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practice alert (BPA) suggesting guideline-recommended MRAs for eligible patients with a serum potassium of <5.0 mEq/L or novel potassium binders for those with a serum potassium of ≥5.0 mEq/L.
Study: 37943300
Drug: Methylprednisolone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (250 mg intravenous injection)
Study: 37943335
Drug: Neuromodulation (noninvasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulation (noninvasive low-level tragus stimulation) 4 hours twice daily (n=8)
Study: 37943351
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy followed by repeat local treatment (thermal ablation and/or surgical resection)
Study: 37943351
Drug: Repeat local
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat local treatment alone
Study: 37943557
Drug: General previsit
Approvals — FDA: no, EMA: no, PMDA: no
Description: General previsit preparation tips for control group physicians and patients.
Study: 37943580
Drug: Unsupervised therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised therapy with an active rehabilitation robot
Study: 37943580
Drug: Minimally supervised
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally supervised therapy
Study: 37943674
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral cessation treatment (ST) + varenicline
Study: 37943674
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral cessation treatment (ST) + placebo
Study: 37944025
Drug: Both synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both synthetic and biological mesh
Study: 37944528
Drug: Tepotinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib (oral MET inhibitor)
Study: 39318203
Drug: EuCorVac-19 (ECV-19)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EuCorVac-19 (ECV-19) vaccine
Study: 37945063
Drug: Bilateral anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral anterior quadratus lumborum nerve block with 60 mL ropivacaine 0.375%
Study: 37945063
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with isotonic saline injections
Study: 37945284
Drug: Filgotinib (FIL)
Normalized name: Nilotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgotinib (FIL) treatment
Study: 37945292
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg/dose, given 24-36 hours apart
Study: 37945297
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose (500-1000 mg infusion at least 21 days prior to surgery)
Study: 37945305
Drug: E-Fit intervention
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-Fit intervention (multimodal and personalised EF intervention) consisting of computer-based EF training using CogniFit Inc 2022, performed three times a week at home; weekly EF remote strategy coaching and analogue games.
Study: 37945305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group following their daily routines and completing a diary about their everyday activities four times a week.
Study: 37945326
Drug: Secondary cytoreductive
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreductive surgery (SCS) followed by non-platinum single agent chemotherapy (paclitaxel, gemcitabine or liposomal adriamycin) for at least 4 cycles
Study: 37945326
Drug: Non-platinum single
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum single agent chemotherapy
Study: 37945413
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (target effect-site concentrations of 0.5, 1, 2, 3, 4 ng/ml)
Study: 37945419
Drug: Community pharmacist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacist-led educational intervention and medication review
Study: 37946117
Drug: Neurotoxic chemotherapy
Normalized name: botulinum neurotoxin A immune FAB2
DrugBank: Equine Botulinum Neurotoxin A Immune FAB2 (DB13900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotoxic chemotherapy
Study: 37946117
Drug: Wearable devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable devices measuring daily gait quality and physical activity
Study: 37946117
Drug: Weekly electronic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly electronic surveys for self-reporting symptoms
Study: 37946136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy (SBRT)
Study: 37946136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atezolizumab, tiragolumab, and SBRT
Study: 37946201
Drug: Mid-treatment decreases
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-treatment decreases in peak PE from imaging
Study: 37946201
Drug: Post-treatment decreases
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment decreases in several DCE-MRI measures
Study: 37946272
Drug: Clear protein
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear protein powder shake (200 ml containing 20 g of whey protein) taken daily for the first 6 months after LRYGB.
Study: 37946283
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DTIC; 375 mg/m2)
Study: 37946283
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) with nivolumab (3 mg/kg)
Study: 37946314
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment, one or two sessions
Study: 37947157
Drug: MK-2206 150
Normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 150 mg weekly (escalation to 200 mg allowed)
Study: 37947190
Drug: Bortezomib (BTZ)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (BTZ) 1.3 mg/m2 body surface area subcutaneously once weekly for 8 weeks followed by oral cyclophosphamide 1 mg/kg/d for 4 months
Study: 37947974
Drug: Vacuum-assisted biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted biopsy (VAB) after neoadjuvant systemic treatment (NAST)
Study: 37948006
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg SC per month (after a 240 mg loading dose)